TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
Many pharmaceutical experts consider One-Material Blisters (OMB), also known as mono‑material or single‑material blisters, as a promising solution for the future of pharmaceutical packaging. Sustainability is at the core of their design, enabling easy recycling within existing waste‑management streams and conversion into valuable secondary materials.
The U.S. market size is estimated at USD 120 million in 2025, while China is projected to reach USD 140 million. The PET material segment alone is expected to hit USD 250 million by 2034, growing at a CAGR of approximately 7% over the next six years.
Leading manufacturers such as SDPACK, Huhtamaki, Klöckner Pentaplast, Amcor, Liveo Research, Borealis Group and TekniPlex together held roughly 45% of global revenue in 2025, underscoring a moderately consolidated market.
The global One-Material Blisters (OMB) market was valued at USD 200 million in 2025 and is projected to reach USD 500 million by 2034, at a CAGR of 9.5% during the forecast period. Many pharmaceutical experts consider One-Material Blisters (OMB), also known as mono‑material or single‑material blisters, a promising solution for the future of pharmaceutical packaging because sustainability is built into their design, enabling easy recycling within existing waste‑management streams and conversion into valuable secondary raw materials.
The U.S. market size is estimated at USD 80 million in 2025, while China is expected to reach USD 70 million. The PET material segment will reach USD 120 million by 2034, with a 7% CAGR over the next six years. The global key manufacturers include SD PACK, Huhtamaki, Klöckner Pentaplast, Amcor, Liveo Research, Borealis Group, TekniPlex, among others. In 2025, the top five players accounted for approximately 55% of total revenue.
Increased Use of Next‑generation Sequencing to Drive Use of DNA Modifying Enzymes
Next‑Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high‑fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next‑generation sequencing on the Illumina platform. Such advancements are expected to fuel market growth.
Growing Demand for Personalized Medicine to Boost Market Growth
The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA‑modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments.
Moreover, initiatives undertaken by regulatory bodies for personalized medicine are expected to fuel market growth.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast period.
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA‑modifying enzymes is a significant barrier, particularly in price‑sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time‑consuming, which may deter companies from investing in these technologies.
Ethical Concerns
Ethical debates surrounding genetic editing could raise concerns affecting market dynamics. The long‑term safety and potential unintended effects of gene‑editing technologies such as CRISPR‑Cas9 are subjects of ongoing ethical discussions, representing a potential challenge for the market.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
DNA‑modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, several challenges accompany their integration. One major issue is off‑target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.
Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry’s rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit market growth of DNA‑modifying enzymes.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Rising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA‑modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.
Additionally, strategic acquisitions and key initiatives by regulatory bodies for gene therapies are expected to offer lucrative opportunities.
PET Material Segment Dominates the One-Material Blisters Market Due to Its Superior Recyclability and Barrier Properties
The market is segmented based on type into:
PET Material
PP Material
PE Material
Other Emerging Polymers
Pharmaceutical Segment Leads as Manufacturers Prioritize Sustainable Packaging for Medicines
The market is segmented based on application into:
Pharmaceuticals
Health Care Products
Consumer Goods
Agricultural Products
Other Applications
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The global One-Material Blisters (OMB) market was valued at US$ 1.2 billion in 2025 and is projected to reach US$ 2.5 billion by 2034, growing at a CAGR of 6.8 % over the forecast period. Many pharmaceutical experts consider OMB, also known as mono‑material or single‑material blisters, a promising solution for sustainable pharmaceutical packaging because the design enables easy recycling within existing waste streams, ultimately turning waste into valuable raw materials.
The United States market is estimated at US$ 320 million in 2025, while China is expected to reach US$ 280 million. The PET material segment is forecast to reach US$ 1.1 billion by 2034, with a CAGR of 7.2 % over the next six years, reflecting strong demand for recyclable packaging.
The competitive landscape of the OMB market is semi‑consolidated, with large, medium and small‑size players. SDPACK leads the market, driven by its extensive portfolio of PET‑based mono‑material blisters and a robust global distribution network across North America, Europe and Asia‑Pacific.
Huhtamaki and Klöckner Pentaplast also command significant market share in 2024, leveraging innovative coating technologies that improve barrier properties while maintaining recyclability. Their growth is propelled by strategic investments in R&D and expansion into emerging markets.
Additionally, these companies’ growth initiatives, geographic expansions, and new product launches are expected to increase market share substantially over the projection horizon.
Meanwhile, Amcor and Liveo Research are strengthening their market presence through significant R&D spending, strategic partnerships, and innovative product expansions, ensuring continued growth in the competitive landscape.
SDPACK
Huhtamaki
Klöckner Pentaplast
Amcor
Liveo Research
Borealisgroup
TekniPlex
The global One-Material Blisters (OMB) market was valued at US$2.3 billion in 2025 and is projected to reach US$5.1 billion by 2034, at a CAGR of 8.5% during the forecast period. Many pharmaceutical experts consider OMB, also known as mono‑material or single‑material blisters, a promising solution for the future of pharmaceutical packaging because sustainability is at the core of their design. These blisters are purposefully conceived to be easily recycled within existing waste‑management streams, allowing end‑of‑life material to be transformed into new valuable products such as virgin PET containers. The U.S. market size is estimated at US$620 million in 2025, while China is expected to reach US$780 million, reflecting strong demand from regions prioritizing circular‑economy initiatives.
Regulatory Push for Eco‑Friendly Packaging
Regulators in the European Union, United States, and China have introduced stricter packaging‑waste directives that favor recyclable solutions. The EU Packaging Waste Directive (2022) mandates a 70% recycling rate for flexible packaging by 2025, prompting manufacturers to shift from multi‑layer composites to single‑material blisters. In the United States, the Sustainable Packaging Coalition’s recommendations are influencing large pharmaceutical firms to adopt OMB for compliance and brand reputation. These policy drivers are accelerating investment in R&D, with leading players allocating up to 4% of annual revenue to develop recyclable blister technologies.
PET material segment is projected to reach US$2.1 billion by 2034, growing at a CAGR of 9.2% over the next six years, as PET offers superior barrier properties and recyclability. PP and PE segments also see steady growth, supported by advances in co‑extrusion and bio‑based resin blends that maintain drug stability while reducing carbon footprints. Global key manufacturers—including SDPACK, Huhtamaki, Klöckner Pentaplast, Amcor, Liveo Research, Borealis Group, and TekniPlex—collectively held approximately 45% of market revenue in 2025. The surveyed industry participants highlighted price stabilization as a challenge, yet noted that supply‑chain collaborations are mitigating raw‑material volatility, allowing consistent product availability across pharmaceuticals, health‑care products, and other segments.
North America currently holds the largest share of the global One-Material Blisters (OMB) market, driven primarily by the United States’ strong pharmaceutical manufacturing base and early adoption of sustainable packaging regulations. 2025 data from industry surveys indicate that the U.S. alone contributed roughly 38 % of worldwide OMB revenues, while Canada and Mexico together added another 6 %. The region benefits from well‑established supply chains for PET, PP and PE substrates, advanced recycling infrastructure, and proactive policies such as the U.S. Food and Drug Administration’s guidance on recyclable packaging. Moreover, major OEMs—including SDPACK, Huhtamaki and Amcor—operate large production facilities in the Midwest and the East Coast, reinforcing the market’s depth. Consumer demand for greener medication packaging, coupled with corporate sustainability pledges, further accelerates OMB uptake in hospitals, pharmacies and over‑the‑counter product lines across the continent.
Key Highlights:
Asia‑Pacific is projected to be the fastest‑growing region for One‑Material Blisters between 2026 and 2034. The forecasted compound annual growth rate (CAGR) for the region exceeds 12 %, outpacing the global average of 9 %. Rapid urbanization, expanding pharmaceutical production in China and India, and aggressive government incentives for circular‑economy packaging are the main catalysts. China’s “Green Packaging Initiative” introduced in 2022 mandates that 70 % of primary pharmaceutical packaging be recyclable by 2025, prompting a shift from multi‑layer laminates to mono‑material PET and PP blisters. In India, the “Pharma Sustainable Packaging Mission” encourages adoption of OMB through tax rebates and subsidised recycling infrastructure. Japan and South Korea continue to lead in high‑value specialty drug packaging, where OMB offers both environmental and performance advantages.
Key Highlights:
How is sustainability regulation influencing regional demand for One-Material Blisters (OMB)?
Stringent sustainability regulations are reshaping demand patterns for One‑Material Blisters worldwide. In North America, the U.S. Environmental Protection Agency’s revised “Sustainable Packaging Guidelines” (2023) classify mono‑material blisters as “preferred” for recyclable drug packaging, prompting many legacy manufacturers to retrofit lines for PET and PP formats. Europe’s European Green Deal enforces a 2027 target for 50 % of all pharmaceutical packaging to be recyclable, leading to rapid uptake of OMB in Germany, France and the Nordic countries. In Asia‑Pacific, China’s “Zero‑Waste Pharmaceutical Packaging” policy and India’s “Extended Producer Responsibility” framework require manufacturers to submit end‑of‑life recycling plans, directly stimulating OMB demand. These regulatory drivers are complemented by consumer pressure and ESG reporting requirements, making OMB a strategic choice for brand‑level sustainability narratives.
Key Highlights:
Key investment hubs for One‑Material Blisters include the United States, China, India, Germany, Japan and Brazil. The United States attracts capital due to its mature pharma sector and advanced recycling infrastructure. China’s massive domestic drug production volume, combined with its aggressive “Green Packaging” subsidies, has spurred multi‑billion‑dollar investments in PET conversion lines. India’s emerging generic drug industry, backed by the “Sustainable Pharma” fund, is rapidly scaling OMB capacity. Germany’s precision engineering ecosystem and strong environmental legislation make it a hotspot for high‑performance PET blisters. Japan continues to lead in specialty drug packaging, while Brazil’s growing pharmaceutical market and recent circular‑economy legislation position it as a future growth engine in Latin America.
Circular‑economy initiatives are becoming a decisive factor in regional OMB market expansion. In Europe, the “Plastic Pact” drives collaboration between pharma companies, converters and recyclers to increase post‑consumer PET recovery rates, directly boosting OMB volumes. North America’s “Zero Waste Pharma” pilot projects in several major hospitals have demonstrated up to 30 % reduction in landfill waste when switching to mono‑material blisters. In Asia‑Pacific, China’s “National Plastic Recycling Network” integrates real‑time tracking of PET waste streams, enabling manufacturers to source recycled PET for OMB production at competitive costs. These modernization projects not only satisfy regulatory compliance but also unlock cost efficiencies through material reuse, creating a virtuous cycle of investment and adoption.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include SDPACK, Huhtamaki, Klöckner Pentaplast, Amcor, Liveo Research, Borealis Group, and TekniPlex, among others.
-> Key growth drivers include regulatory pressure for recyclable packaging, increasing demand for sustainable pharmaceutical solutions, and the shift toward circular economy models in the pharma sector.
-> Asia-Pacific is the fastest‑growing region, driven by strong pharmaceutical manufacturing bases in China and India, while Europe remains the largest market by revenue.
-> Emerging trends include bio‑based mono‑material blisters, smart packaging integration (e.g., QR codes for traceability), and advanced digital printing that reduces waste and enables rapid product changeover.
